A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis.

Inclusion Criteria:

1. Presence of specific signs and symptoms of Oropharyngeal Candidiasis, includingerythematous areas, white patches(thrush), mouth pain, irritation, burning, glossitis,altered taste, pruritis, dysphagia and odynophagia.

2. Clinical examination of oropharynx consistent with a diagnosis of oral candidiasis (such as creamy, white, curd-like patches of "thrush" or erythematous lesions onmucosal surfaces).

3. Confirmation of Candidiasis by findings on direct microscopic examination (potassiumhydroxide smear) consistent with Candida species or positive fungal culture forCandida species, with culture obtained in the 2 days preceding initiation of therapywith the study drug.

4. Subjects who are able and willing to give Informed Consent.

Exclusion Criteria:

1. Female subjects who are pregnant, lactating or planning to become pregnant during thestudy period.

2. Subjects diagnosed with disseminated candidiasis or requiring systemic antifungaltherapy.

3. Subjects diagnosed with hairy leukoplakia.

4. Presence of only perioral lesions, e.g., angular chelitis.

5. History of intolerance or sensitivity to clotrimazole (or other imidazole or azolecompounds) or any constituent of Roxane ® or the generic Clotrimazole Troche/ Lozengesor unable to tolerate oral medication.

6. Subjects having history of resistance to treatment with clotrimazole (Subject who areresistant to Clotrimazole after culture and sensitivity test have to be excluded fromthe study).

7. Subjects who have received any oral or systemic antifungal therapy within fourteen (14) days prior to randomization.

8. Subjects who have received any investigational therapy within 30 days prior torandomization.

9. Subjects who have been diagnosed with any concomitant condition that, in the opinionof the investigator, could interfere with the evaluation of efficacy or safety, orwould make it unlikely that the subject would complete the study.

10. Subjects who have been treated with protease inhibitors for the first time within 30days.

11. Subjects who have been taking medications known to have significant interaction withazoles (e.g., antacids, H2-receptor blockers, rifampin, phenytoin, carbamazepine,astemizole).

12. Subjects who have a history of candidal prophylaxis with any azole antifungalmedication.

13. Any subject with recurrent Oropharyngeal Candidiasis.

14. Any subject who is chronically infected with Candida.

15. Any subject with baseline liver function tests greater than 3 times the upper limit ofnormal (ULN).

16. CD4 cell count less than 200 cells/mm3. 17. Absolute neutrophil count less than 500/mm3.

17. Subject with history of Type II Diabetes Mellitus with Uncontrolled Blood Sugar levels. (I.e. Random Blood Sugar level > 350).

18. Suspected inability (or) unwillingness to comply with the study procedures.